Search Results

04 March 2025, Singapore In picture: From left: Dr Ian Cheong, Mr Peter Chia, Dr Chris Tan, Mr Kevin Lee In a significant development for the clinical diagnostics landscape in Singapore, Angsana Molecular & Diagnostics Laboratory (Angsana) and Pathnova Laboratories (Pathnova) have announced their merger to form Archerfish Precision Diagnostics Private Limited (Archerfish) . This strategic union brings together two leading laboratory players with complementary expertise – Angsana in molecular diagnostics and Pathnova in serology and AI – This merger positions Archerfish as a powerhouse in advanced diagnostic solutions. ​ The merger seeks to combine the unique strengths of both laboratories, expanding their capabilities beyond their current portfolio to offer a comprehensive range of advanced diagnostic assays. ​ Angsana is a pioneer in the field of molecular oncology in Asia, having introduced clinical Next-Generation Sequencing (NGS) early on. They have a strong track record of successful commercialisation and bringing clinical diagnostics tests to the market. Pathnova specialises in the development and manufacturing of diagnostic products, including the creation of intellectual property related to novel diagnostic technologies, exemplified by their proprietary early screening test for nasopharyngeal cancer. Both labs are focused on diseases prevalent in Asia. ​ Archerfish will cater to both the private and public healthcare sectors, enhancing access to innovative and accurate diagnostic services. Advancing Diagnostic Innovation Archerfish's vision is to be at the forefront of diagnostic innovation, providing accurate, timely, and comprehensive solutions for early cancer screening, as well as precision diagnostics guiding treatments for cancer and other diseases. ​ By leveraging cutting-edge technologies and pioneering research, the company is expanding its portfolio of diagnostic tests to drive innovation in clinical practice. ​ Next-Generation Sequencing ​ One key area of development is advancing Next-Generation Sequencing (NGS) beyond personalized cancer care to other areas including infectious disease detection. For instance, metagenomic NGS (mNGS) enables the comprehensive identification of microorganisms, offering the potential to detect a wide range of viral and bacterial infections from a single plasma sample within a clinically actionable timeframe. ​ Data-Driven Disease Detection ​ In addition, the company is developing data-driven approaches to disease detection through serum proteomics and serological profiling. Advances in aptamer technology now allow for the profiling of thousands of proteins in serum, providing a versatile and powerful tool for diverse diagnostic applications. ​ Artificial Intelligence ​ To maximise the potential of these data-driven methods, Archerfish is integrating artificial intelligence to refine pattern analysis, improving disease detection and predictive accuracy. Through these innovations, the company remains committed to transforming diagnostics and enhancing patient outcomes. ​ The above contains forward-looking statements that are subjected to further technology and market research. ​ Strategic Leadership and Investment Archerfish's management team comprises leading clinicians, scientists and accomplished healthcare executives, providing the vision and leadership necessary for the company's growth. Their combined expertise in diagnostics, research, and business strategy aims to keep Archerfish at the industry's forefront in Asia. ​ The merger is backed by a consortium of strategic investors including Temasek Life Sciences Laboratory, The Life Sciences Innovation Fund, Temasek Life Sciences Accelerator and SEEDS Capital, which fund and support research and innovation. With such backing, Archerfish is well positioned to achieve its ambitious goals. ​ Collaborative Efforts and Future Plans The formation of Archerfish is expected to facilitate greater collaboration in public-private partnerships, contributing to healthcare cost efficiency through economies of scale. By working closely with government agencies and healthcare providers, Archerfish aims to improve access to high-quality diagnostic services. ​ Archerfish is seeking to raise at least SGD$50 million over the next three years to support its expansion plans. This funding will be used to further develop and commercialise its innovative diagnostic solutions as well as regional expansion. ​ "This merger represents a significant step forward in our mission to advance diagnostic science and improve patient outcomes," said Dr. Lim Cheok Peng, Chairman of Archerfish Precision Diagnostics, Founder of Angsana Molecular & Diagnostics Laboratory. ​ "Archerfish will address a critical gap in Singapore’s clinical laboratory landscape, seamlessly translating scientific evidence into practical, high-quality clinical laboratory solutions," added Dr. Ian Cheong, Director of Archerfish Precision Diagnostics and Co-founder of Pathnova Laboratories. ​ "The merger of these two laboratories fosters a dynamic synergy, uniting expertise and resources to drive groundbreaking innovation and create a greater positive impact on society," said Mr Peter Chia, CEO of Temasek Life Sciences Laboratory.   About Archerfish Precision Diagnostics Archerfish Precision Diagnostics Private Limited is a leading molecular diagnostics company dedicated to innovative solutions for cancer detection and treatment. Formed through the merger of Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories, both CAP-accredited laboratories, Archerfish combines excellence in clinical laboratory practice with a strong commitment to research and development.   ​ Contact Information Angeline Wong Senior Strategic Development Manager angeline.wong@archerfishdx.com In picture: Standing from left: Dr Brendan Pang, Dr Benedict Yan, Dr Brian Wang, Mr Jason Foo, Dr Venkateswaran Natarajan. Seated from left: Dr Ian Cheong, Dr Lim Cheok Peng, Mr Kevin Lee

24 July 2025, Singapore Archerfish Precision Diagnostics (Archerfish), a premier diagnostic laboratory serving Singapore and the broader Asian region and C2N Diagnostics, LLC (C2N), a leader in advanced brain health diagnostics, today announced a strategic partnership to introduce and expand access to C2N's innovative blood-based diagnostic test for Alzheimer's Disease (AD). This collaboration marks a significant step forward in improving early and accurate diagnosis of AD, a critical need across Asia.​ The partnership will leverage Archerfish's extensive network and expertise in laboratory services and patient outreach throughout Singapore and other key Asian markets. This will facilitate the widespread availability of C2N's cutting-edge PrecivityAD2™ blood test, which offers a less invasive and more accessible method for detecting amyloid pathology in the brain, a hallmark of AD, all through a single blood draw. Embracing breakthrough technology in Alzheimer’s Disease diagnostics This innovative diagnostic test is the first of its kind in Singapore and signals a step towards more accessible, non-invasive AD diagnostics. The PrecivityAD2™ blood test is intended for individuals 55 and older who are being evaluated by a healthcare provider for AD or other causes of cognitive decline. Using high resolution liquid chromatography, tandem mass spectrometry, PrecivityAD2™ detects specific amyloid beta and tau peptides circulating in blood that are associated with the presence of amyloid plaques in the brain that can aid healthcare providers in the diagnosis of AD. Early and accurate diagnosis of AD is paramount for several reasons: it allows patients and their families to plan for the future, access appropriate care and support services, and potentially enrol in clinical trials for emerging therapies. Traditional diagnostic methods can be invasive, costly, and often inaccessible in many regions. C2N's PrecivityAD2™ blood test aims to overcome these barriers, providing a more convenient and scalable solution.  Addressing Alzheimer’s Disease in Singapore’s Ageing Population In light of a rapidly ageing population, this partnership seeks to strengthen local capabilities for AD diagnosis. Currently, approximately 1 in 11 adults aged 60 years and over suffer from dementia, including AD¹. By 2030, around 1 in 4 citizens (24.1%) will be aged 65 & above.² Given that the risk of dementia increases with age, Singapore will likely see a rise in the number of cases as her population continues to age, highlighting the need for accessible yet highly accurate diagnostic tools such as PrecivityAD2™. While cognitive issues may have many potential causes, the PrecivityAD2™ blood test can provide greater clarity in an AD diagnosis. The PrecivityAD2™ test result is a clinically validated algorithm that can either confirm the presence of amyloid pathology and increase confidence in an AD diagnosis to enable patients to take timely action to manage their condition or rule out AD as a cause for cognitive decline, thus avoiding additional rounds of testing and accelerating a timely intervention. In either case, PrecivityAD2™ empowers healthcare providers and patients to improve healthcare outcomes through increased diagnostic certainty.  “We are delighted to partner with Archerfish to bring our advanced AD diagnostic solution to patients and clinicians in Singapore and across Asia,” said Joel Braunstein, CEO and President of C2N. “This collaboration aligns with our mission to transform brain health by providing innovative, accessible, and reliable diagnostic tools. Archerfish's deep understanding of the regional healthcare landscape and their commitment to excellence make them an ideal partner to help us address the growing burden of Alzheimer's disease in this part of the world.” Dr Chris Tan, Group Chief Executive Officer, Archerfish Precision Diagnostics commented, “Archerfish is committed to bringing the most advanced and impactful diagnostic technologies to our patients. The partnership with C2N Diagnostics represents a pivotal moment in our efforts to combat AD in Asia. We believe that C2N’s PrecivityAD2™ will revolutionize how AD is diagnosed, enabling earlier intervention and better patient outcomes. We look forward to working closely with C2N to ensure broad access to this vital test.” “Accurate and accessible diagnosis is an important cornerstone in the management of Alzheimer’s Disease. With advances in blood-based biomarkers, we are seeing new possibilities that complement standard diagnostic methods and support more timely clinical decision-making. Such developments hold promise for improving care for individuals experiencing cognitive decline,” said Professor Christopher Chen, Director, Memory Aging and Cognition Centre, National University Health System.  ​​​ ​​About Archerfish Precision Diagnostics Archerfish Precision Diagnostics is a company focused on developing and launching novel diagnostic tests that address the unique healthcare requirements of the Asian community. It leverages an expert team comprising leading scientists, healthcare administrators, and molecular pathologists to unify first-in-class diagnostics and introduce them to Singapore and the broader Asian market. Formed through the merger of Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories, both CAP-accredited laboratories, Archerfish combines excellence in clinical laboratory practice with a strong commitment to research and development.  About C2N Diagnostics C2N Diagnostics is a U.S-based specialty diagnostics company dedicated to advancing the field of brain health through cutting-edge diagnostic technology. Their innovative products and services enhance patient care and support clinical trials for neurodegeneration treatment. With strong foundations in scientific research and global clinical partnerships, C2N remains committed to transforming the way brain disorders are diagnosed, understood, and treated around the world. ​ Contact Information Archerfish Precision Diagnostics Angeline Wong angeline.wong@archerfishdx.com C2N Diagnostics Joni Henderson joni.henderson@c2n.com ​​​​ ¹ Subramaniam M, Abdin E, Asharani PV, Roystonn K, Devi F, Peizhi W, et al. Prevalence of dementia in Singapore: Changes across a decade. Alzheimer’s & dementia : the journal of the Alzheimer’s Association. 2025;21(2):10.1002/alz.14485. https://pubmed.ncbi.nlm.nih.gov/39868432/ ²  https://www.population.gov.sg/files/media-centre/publications/population-in-brief-2023.pdf​